eXmoor Pharma, a provider of cell and gene therapy manufacturing services, has achieved a significant milestone with the receipt of a Manufacturing and Import Authorization for Investigational Medicinal Products (MIA(IMP)) license from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). This authorization allows eXmoor to manufacture good manufacturing practice (GMP)-grade cell and gene therapy materials for use in clinical trials.     The licensure follows a rigorous in...